Platinum-based anticancer drugs are foundational in the treatment of several types of cancers. An important research objective is to identify novel platinum(II) complexes that exhibit anti-cancer properties and have reduced toxicities. The goal of this project was to study the effects of the leaving ligand on anti-cancer activity by exchanging the chloride leaving ligand on the existing monofunctional platinum compounds, including phenanthriplatin and pyriplatin, with an acetate group. Phenanthriplatin and pyriplatin were synthesized according to the methods in the literature and reacted with silver acetate to form insoluble silver chloride and the desired platinum compound. The resulting substances were evaluated and monitored for dissociation of the acetate group via nuclear magnetic resonance (NMR) spectroscopy. Additionally, phenanthriplatin and pyriplatin were dissolved separately in deuterium oxide and monitored again via NMR spectroscopy for changes occurring in solution over time. This information was used in conjunction with the NMR spectra obtained from the reactions with silver acetate to help determine the properties of the synthesized compounds. Lastly, phenanthriplatin and pyriplatin were reacted with 5’-guanosine monophosphate (5’-GMP) to determine potential reactivity with the biological target.

Leaving ligand effects on solubility and reactivity of monofunctional platinum compounds

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.